Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company’s international commercial sales and operations functions.

"We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion’s Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expanding by the day and presenting Allurion new opportunities for growth. Adrian’s expertise in building sustainable commercial organizations will be vital to our long-term success plans.”

“This is a great time to join Allurion as it enters a new stage of growth and development in an ever-expanding market,” said Mr. Wild. “I look forward to working with the talented team at Allurion to capitalize on this opportunity and take the company’s commercial organization to new heights.” Mr. Wild brings a wealth of experience in driving business growth and operational excellence across global markets. For over a decade, he held leadership roles at Align Technology where he contributed to establishing a new standard of care and oversaw Align’s expansion in Europe to become an international market leader. Immediately prior to joining Allurion, he served as SVP and Head of Western Europe at Straumann Group, a global leader in dental implants and orthodontic solutions, where he helped Straumann achieve significant growth through strategic marketing and operational initiatives. Prior to Straumann, Mr. Wild was VP, Commercial Excellence Global at Mölnlycke Health Care, a global medical technology company specializing in wound care and surgical solutions where he helped improve commercial effectiveness across more than 100 countries.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820207152/en/